Pharma’s Next Act: More R&D, More Asia, Fewer Easy Deals

For decades, the pharmaceutical investment thesis was relatively straightforward: rising healthcare demand funded larger R&D budgets, innovation remained concentrated in the US and Europe, and an expanding ecosystem of CROs, CDMOs, and other service providers captured a growing share of industry spending.

That thesis is not disappearing. But it is getting considerably more complicated.

Global pharmaceutical demand remains structurally supported by aging populations and chronic disease. McKinsey estimates global pharmaceutical sales could grow at roughly 5% annually, while advanced therapies have already increased their share of industry sales from 30% in 2018 to more than 40% in 2024, with that figure expected to approach 45% by 2030.

At the same time, the economics underneath that growth are changing.

R&D spending has climbed dramatically, but investors increasingly care about productivity rather than spending alone. Asia—and China in particular—is becoming an originator of drugs rather than merely a manufacturer of them. And private equity’s once relatively straightforward bet on the outsourced pharma ecosystem has entered a much more selective phase.

In other words, pharma is still growing. The easy part may be over.

More R&D, but also more pressure to make it productive

The first number worth watching is $306 billion.

That was global pharmaceutical R&D spending in 2024, according to EvaluatePharma data, nearly double the $161 billion spent in 2016. Spending is projected to continue increasing toward approximately $366 billion by 2030.

Caption suggestion: R&D spending has nearly doubled since 2016, but higher budgets are raising the bar for productivity.

The growth makes intuitive sense. The industry is pursuing more scientifically complex products, from biologics and antibody-drug conjugates to cell and gene therapies. More advanced therapies can offer greater clinical differentiation and pricing power, but they also bring more complex discovery, clinical development, manufacturing, and regulatory requirements.

There is also simply more science to fund. The global pharmaceutical pipeline expanded from 5,995 active drugs in 2001 to 22,825 in 2024, according to our previous analysis of Pharma Intelligence data.

But more shots on goal do not automatically produce better returns.

Drug development remains a business defined by long timelines, high failure rates and large upfront costs. McKinsey describes traditional economics through the familiar “ten-year, 10% success rate” framework. Successful drugs ultimately need to recover not only their own development costs, but also the capital consumed by candidates that never reach commercialization.

And there is another constraint: the clock is running.

Pharmaceutical patents are typically filed during development and generally provide 20 years of protection from filing. Because discovery, trials and regulatory review consume part of that period, delays reduce the effective commercial window available after approval. McKinsey estimates effective commercial exclusivity can often be only 10 to 14 years following approval.

That makes speed an economic variable, not just an operational KPI.

A drug that reaches market faster does not merely cost less to develop. It potentially gains additional years of protected revenue. Conversely, a slow development program can destroy value twice: first through higher R&D expenditure and then through a shorter commercialization window.

That distinction matters as R&D budgets approach record levels.

For investors, the relevant question is shifting from “who spends the most?” to “who converts R&D dollars into valuable assets most efficiently?”

And that is where both AI and a changing global innovation map enter the equation.

AI moves from science experiment to productivity tool

AI has spent several years occupying an awkward position in pharma: simultaneously described as transformational and difficult to quantify.

The more compelling investment case is less futuristic.

AI does not need to autonomously invent the next blockbuster drug to create value. It can improve target identification, trial design, regulatory workflows, manufacturing and the ability to terminate weak programs earlier—all areas where relatively small improvements in speed or probability of success can have disproportionate economic consequences.

That framing is increasingly visible among operators. In Deloitte India's 2026 survey, 76% of pharmaceutical CXOs said they were prioritizing robotics, automation and AI-driven regulatory tools. Companies were also prioritizing biologics, biosimilars, new chemical entities and digitally enabled drug discovery.

The economic logic is straightforward: when development timelines can stretch beyond a decade, saving time is effectively creating patent life.

But technology is only one part of the productivity story.

The other is geography.

Asia is no longer just pharma’s factory

For years, the industry's geographic division of labor was easy to understand.

The US and Europe produced much of the original science and commercialized the highest-value medicines. Asia provided manufacturing capacity, generics, lower-cost development infrastructure and increasingly important end markets.

That map is being redrawn.

Asia's share of the global innovative drug pipeline increased from 28% to 43% in just five years, surpassing both the US and Europe. Even more strikingly, Asia generated more than 85% of global growth in innovative drug pipelines in 2024.

China is the primary engine. It now represents roughly 29–30% of the global innovative biopharma pipeline, compared with only around 2% a decade ago.

That is not a manufacturing story. It is an innovation story.

Asian companies generated nearly two-thirds of biotech patent grants in 2024, according to McKinsey, and accounted for roughly a quarter of global out-licensing deals. Upfront payments from China-originated out-licensing transactions rose from below $100 million in 2020 to more than $800 million in 2024.

The traditional Western pharma model therefore faces a new competitor—and potentially a new source of assets.

China's advantage is not solely cheaper scientists. It increasingly comes from an integrated ecosystem combining research talent, CROs, CDMOs, clinical sites and development infrastructure with faster execution.

McKinsey's modeled comparison is striking: developing a successful biopharma therapy costs a multinational company approximately 2.7x more than a Chinese company on a levelized basis under its fast-follower case. Time-to-market explains roughly 40% of that cost difference. Discovery in the model takes around 36 months in China versus 54 months globally, while development takes 87 months versus 100 months.

That creates an uncomfortable competitive dynamic for Western pharma.

The advantage is no longer simply lower cost. It is potentially lower cost + faster development + increasingly competitive science.

And China is not the whole story.

South Korea has built capabilities across discovery, development and advanced biologics manufacturing. Singapore has established itself as a focused biomedical R&D hub. Japan retains deep basic science and commercialization capabilities. India, meanwhile, is attempting its own transition from a generics and manufacturing powerhouse toward higher-value innovation.

Deloitte's latest India survey captures the direction of travel: 86% of pharma CXOs expect 5–15% growth in FY27, while around 55% plan to expand manufacturing capacity by 10–30% over the next two to three years. India's growing CDMO capacity and AI-enabled R&D ecosystem are increasingly targeting areas such as GLP-1s, oncology, biologics, and cell and gene therapies.

For Western pharma companies, Asia therefore becomes two things at once: a competitive threat and an increasingly valuable source of innovation.

For investors, that distinction matters even more.

An Asian biotech does not necessarily need to build a global commercial organization to monetize its science. It can develop an asset quickly, demonstrate clinical value and license it to a multinational with global distribution and regulatory capabilities.

That creates a different global division of labor—one based less on manufacturing versus innovation and more on who can discover, develop, finance and commercialize each asset most efficiently.

From one global pharma market to several

The geographic shift is also colliding with geopolitics.

For decades, large pharma could largely operate under what Bain describes as a “one world, one molecule” model: discover a drug, develop it globally and commercialize the same asset across major markets.

That assumption is weakening.

Drug pricing policies, local manufacturing incentives, supply-chain security, regulatory divergence and geopolitical considerations are pushing the industry toward what Bain calls a multipolar pharma market.

China is perhaps the clearest example. It is becoming both a major source of innovation and a commercial market with its own competitive and reimbursement dynamics. Meanwhile, Europe is emphasizing domestic supply through initiatives such as the Critical Medicines Act, while the US is using industrial policy to encourage domestic manufacturing.

The capital flows are already visible.

McKinsey estimates that announced US greenfield investment in advanced pharmaceutical manufacturing jumped from approximately $18 billion in 2024 to $180 billion in 2025. The economics do not necessarily make the US the cheapest location—labor remains significantly more expensive—but regulatory credibility, IP protection, supply-chain resilience and industrial policy increasingly influence investment decisions alongside pure manufacturing cost.

This creates another important shift in pharma economics.

Efficiency and resilience are no longer always pointing in the same direction.

The cheapest R&D ecosystem, manufacturing location or supplier may not be the politically safest one. Conversely, reshoring production can improve supply-chain security while increasing the importance of automation and AI to offset higher labor costs.

For executives, capital allocation becomes more complex. For investors, geography becomes part of underwriting rather than background context.

And nowhere is that changing underwriting more visible than in pharma services.

Pharma services: from easy growth to selective capital

The outsourcing thesis behind pharma services remains compelling.

Drug development is expensive and increasingly specialized. Pharma and biotech companies rely on CROs for research and clinical execution, CDMOs for development and manufacturing, and a broad ecosystem of commercialization, data and regulatory providers. McKinsey notes that most biopharma companies already outsource portions of discovery support, preclinical work, trial operations and data management.

That created an attractive formula for private equity: secular pharma growth + outsourcing penetration + fragmented providers + recurring demand.

For years, it worked.

Then came 2021.

Caption suggestion: The 2021 dealmaking peak is long gone. Pharma services PE activity is now searching for a floor.

PitchBook's data makes the reset hard to miss. Pharma services PE deal count surged to 441 transactions in 2021, with $59.9 billion of deal value. Activity remained elevated in 2022 before beginning a multiyear normalization. By 2025, the chart shows 189 deals and $34.3 billion in aggregate value; 2026 data through the period shown stands at 127 estimated deals and $11.7 billion of value.

PitchBook's title for its Q2 2026 pharma services report says it succinctly: “Finding a Floor.” The report focuses on the industry's evolving PE investment environment after the post-pandemic reset.

But fewer transactions should not be confused with a broken investment thesis.

The more interesting story is what PE is still willing to buy.

Caption suggestion: Pharma services deal volume has moved against the broader healthcare recovery.

Bain estimates pharma services buyout volume declined at approximately an 11% CAGR from 2023 through 2025E, while other healthcare PE deal volume grew at an 11% CAGR over the same period.

Several forces explain the divergence.

Biotech funding normalized after the extraordinary 2020–21 cycle. Clinical trial starts—particularly in early-stage programs and drug discovery—also moved back toward pre-pandemic levels. Pricing pressure on pharma sponsors tightened budgets. Policy and trade uncertainty increased. And, perhaps most importantly for PE, buyers and sellers have struggled to agree on price.

Many assets bought at 2021–22 multiples remain in sponsor portfolios. Average transaction multiples have declined since then, but Bain says they remain above pre-pandemic levels. That has created the familiar private-equity stalemate: buyers remember today's cost of capital; sellers remember yesterday's valuation.

Yet the value side of the market tells a different story.

Caption suggestion: Fewer deals, but not necessarily less conviction: capital is concentrating in larger, higher-quality assets.

While pharma services deal count declined, Bain's data shows deal value moving in the opposite direction, with pharma services buyout value growing at a 27% CAGR between 2023 and 2025E.

That apparent contradiction may be the most useful signal in the entire dataset.

Private equity has not abandoned pharma services. It has raised the bar.

Bain says 2025 was the largest year on record for pharma services transaction value, although the result was heavily influenced by a handful of large assets. The investment in PCI Pharma Services alone represented more than one-third of the year's value. Other notable transactions targeted clinical trial site networks and specialized service providers.

The emerging PE playbook is consequently more selective: differentiated assets with scale, stronger revenue visibility, exposure to large pharma rather than funding-sensitive early-stage biotech, and businesses operating in niches that are less vulnerable to policy or macro volatility. Investors are also looking at under-optimized platforms where operational improvements can create value rather than relying primarily on multiple expansion.

That is a very different market from 2021.

Back then, abundant capital could reward exposure to a broad outsourcing tailwind. Today, quality of revenue, customer mix, differentiation, operational leverage and entry valuation matter much more.

In private equity terms, pharma services is moving from a beta trade to an alpha trade.

The paradox: R&D is rising while services deals are falling

Put the charts next to each other and the industry's central paradox becomes clear.

Pharma is spending more on R&D. The pipeline is expanding. Advanced therapies are taking a larger share of sales. Asia is creating more drug candidates. And outsourcing remains embedded throughout discovery, development and manufacturing.

Yet PE deal volume in pharma services is falling.

Those facts are not contradictory.

They show the difference between industry growth and investment returns.

A growing end market can still produce mediocre investments when entry valuations are too high, customers become more selective, financing costs rise or competitive differentiation disappears. Likewise, a temporarily slower transaction market can contain excellent assets if long-term demand remains intact.

This is why the current cycle may ultimately be healthier for investors.

The 2021 environment rewarded access to capital. The next one is more likely to reward underwriting.

Sponsors will need to distinguish between outsourcing businesses that simply sit downstream of higher R&D spending and those that genuinely capture it. CROs with differentiated therapeutic expertise, CDMOs serving complex modalities, clinical networks with scarce patient access, and service businesses with long-duration contracts may have very different economics from commoditized providers competing primarily on price.

AI adds another layer.

It can improve margins and throughput for service providers, but it can also automate work customers previously paid them to perform. The winners will not necessarily be the companies with the most AI branding; they will be those that use technology to shorten timelines, improve quality or make scarce expertise more scalable.

The same principle applies across the entire pharma value chain.

More spending is useful. Better productivity is valuable.

The Bottom Line

Pharma's next cycle is unlikely to look like its last one.

The structural demand case remains powerful: aging populations, chronic disease and new therapeutic modalities should keep global drug demand growing. R&D spending is already above $300 billion, and the scientific opportunity set continues to broaden.

But where value accrues is changing.

Asia has gone from supporting Western pharmaceutical innovation to increasingly producing it. China alone now accounts for roughly 30% of the global innovation pipeline, while Asia as a whole represents 43%.

Meanwhile, the global model is fragmenting. Companies must balance cost efficiency against resilience, global scale against local regulation, and scientific ambition against increasingly demanding R&D economics.

Private equity is responding accordingly. Pharma services deal volume has fallen, but capital continues to chase large, differentiated assets with scale and visibility. The outsourcing thesis survived. The indiscriminate version of it did not.

For investors, that may be the defining feature of pharma's next act.

There will be more R&D. More science will come from Asia. AI may compress parts of the development cycle. Pharma will continue outsourcing critical functions.

But simply being exposed to those trends will not guarantee returns.

The next winners will be the companies—and the investors—that can turn more innovation into better economics.

Sources & References

McKinsey Global Institute, Pharmaceuticals: Innovating and Advancing Around the World. https://www.mckinsey.com/mgi/our-research/pharmaceuticals-innovating-and-advancing-around-the-world

McKinsey & Company, The Emerging Epicenter: Asia’s Role in Biopharma’s Future. https://www.mckinsey.com/industries/life-sciences/our-insights/the-emerging-epicenter-asias-role-in-biopharmas-future

McKinsey Global Institute, Biopharma R&D: The Evolving Formula for Discovery and Development. https://www.mckinsey.com/mgi/our-research/biopharma-r-and-d-the-evolving-formula-for-discovery-and-development

Deloitte, Healthcare and Pharmaceuticals Enter the Next Phase of Growth with AI-led Transformation. https://www.deloitte.com/in/en/about/press-room/healthcare-and-pharmaceuticals-enter-the-next-phase-of-growth-with-ai-led-transformation-deloitte-india.html

Bain & Company, Managing the Transition to a Multipolar Pharma Market. https://www.bain.com/insights/managing-the-transition-to-a-multipolar-pharma-market/

PitchBook, Q2 2026 Pharma Services Report: Finding a Floor. https://pitchbook.com/news/reports/q2-2026-pharma-services-report-finding-a-floor

Bain & Company, Playing the Long Game in Pharma Services: Global Healthcare Private Equity Report 2026. https://www.bain.com/insights/playing-the-long-game-in-pharma-services-global-healthcare-private-equity-report-2026/